sufentanil sublingual

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Moderate-to-severe Acute Pain

Drug Information

Target Indication

Moderate-to-severe Acute Pain

Clinical Trial

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA6/25/2018

Dzuveo

Dzuveo is indicated for the management of acute moderate to severe pain in adult patients.

Drug Science

Mechanism of action & safety profile

Developer

TLPH

TALPHERA, INC.

Related Pipeline

Moderate-to-severe Acute Pain

Pain, Postoperative

Post-Operative Pain

Post-Operative Pain

Post Operative Pain

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts